title: [Transsphenoidal surgery for prolactinomas: results and prognosis].
abstract: OBJECTIVE
  The aim of this study was to explore the long-term outcomes of surgery for transsphenoidal prolactinomas and the factors that influence them.
  
  
  METHODS
  Transsphenoidal approach for pituitary adenomas has been applied to 329 patients in the Department of Neurosurgery of Kaunas University of Medicine Hospital in the period of 1995 to 2006. Of these, 85 patients were operated for prolactinomas.
  
  
  RESULTS
  Of the 85 patients operated on for prolactinomas, 68 (80%) were females and 17 (20%) were males. Thirty-two microprolactinomas and 36 macroprolactinomas were diagnosed in women and 16 and 1, respectively, in men. Twenty (23.5%) patients (16 women and 4 men) had visual field defects before the operation. Dopamine agonist therapy was administered in 50 patients (38 women and 12 men) before the operation. Of 10 women, in whom microadenoma was diagnosed and no dopamine agonist therapy was prescribed, remission was achieved in 9 (90%) patients after the operation, while of 22 women, who was treated with dopamine agonists before the operation, remission was achieved only in 10 (45.5%) (P=0.01). Each year of age decreased the chance of remission by 8%.
  
  
  CONCLUSIONS
  Remission after the surgical treatment was achieved in 11.8% of men and 47.1% of women with prolactinomas. Remission rate was very high (90%) among women with microprolactinoma not treated with dopamine agonist before the surgical treatment. The probability of a good outcome of surgery among women with prolactinoma was related to younger age of the patient, noninvasive tumor growth, plasma prolactin level less than 2309 mU/L, and no use of dopamine agonist before the surgical treatment.
authors.affiliation: Department of Neurosurgery, Kaunas University of Medicine, Eiveniu 2, 50009 Kaunas, Lithuania. kestassinkunas@takas.lt
authors.forename: Kestutis
authors.initials: K
authors.lastname: Sinkūnas
authors.forename: Daiva
authors.initials: D
authors.lastname: Rastenyte
authors.forename: Vytenis Pranas
authors.initials: VP
authors.lastname: Deltuva
authors.forename: Robertas
authors.initials: R
authors.lastname: Knispelis
authors.forename: Arimantas
authors.initials: A
authors.lastname: Tamasauskas
mesh_terms: D000328:Adult; D016009:Chi-Square Distribution; D018491:Dopamine Agonists / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D016015:Logistic Models; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D010911:Pituitary Neoplasms / Q000175:diagnosis / Q000000981:diagnostic imaging / Q000601:surgery*; D011300:Preoperative Care; D011379:Prognosis; D011388:Prolactin / Q000097:blood; D015175:Prolactinoma / Q000175:diagnosis / Q000000981:diagnostic imaging / Q000601:surgery*; D012074:Remission Induction; D012737:Sex Factors; D013997:Time Factors; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
chemical_list: D018491:Dopamine Agonists; D011388:Prolactin